TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

Major depressive disorder (MDD ... only a third of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core depressive or residual ...

Cybin Inc. CYBN has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

Emerging research suggests that chronic inflammation, rather than neurotransmitter deficiencies alone, may be a major factor ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into ...